Establishment of optimal supportive care for prevention of drug-induced kidney injury using medical big data

2023 Fiscal Year Final Research Report

• Project/Area Number: 20K16077
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 47060:Clinical pharmacy-related
• Research Institution: The University of Tokushima
• Principal Investigator: SAKURADA Takumi 徳島大学, 病院, 薬剤師 (10846364)
• Project Period (FY): 2020-04-01 – 2024-03-31
• Keywords: 薬剤性腎障害 / 医療ビッグデータ解析 / ドラッグリポジショニング / 病態モデル解析

Outline of Final Research Achievements

Cisplatin is effective in many types of carcinoma. However, high rates of renal injury are a clinical problem. On the other hand, new prophylaxis methods are needed, as the prevention methods currently used in clinical practice do not completely prevent renal injury. Therefore, the aim of this study was made to explore prophylactic agents with high potential for clinical application. Cascade Eye, a drug discovery AI, LINCS, a gene expression database, and FAERS, a large adverse drug reaction reporting database, were used to identify drugs that can prevent cisplatin-induced kidney injury in clinical practice.
Studies using HK2 cells and mouse models showed that fenofibrate significantly inhibited cisplatin-induced renal injury but did not inhibit the antitumor effect of cisplatin. Fenofibrate is a candidate prophylactic drug with high clinical applicability for cisplatin-induced renal injury.

Free Research Field

臨床薬理学

Academic Significance and Societal Importance of the Research Achievements

本研究では、医療ビッグデータ解析、細胞実験、動物実験を組み合わせた研究手法により、現在も臨床で使用されている脂質異常症治療薬であるフェノフィブラートが臨床応用可能性の高いシスプラチン誘発腎障害予防薬となる可能性を示した。